Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 10 Uterine Cervical Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 6 Stomach Neoplasms 5 Triple Negative Breast Neoplasms 4 Pancreatic Neoplasms 4 Carcinoma, Renal Cell 4 Advanced Solid Tumors 4 Urinary Bladder Neoplasms 3 Recurrence 3 Melanoma 3 Lung Neoplasms 3 Cholangiocarcinoma 3 Solid Tumor 2 Ovarian Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Kidney Neoplasms 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Adenocarcinoma Of Esophagus 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Urothelial Bladder Carcinoma 1 Thyroid Carcinoma, Anaplastic 1 Thymoma 1 Solid Tumors 1 Solid Tumor, Unspecified, Adult 1 Sarcoma 1

Interventions

pembrolizumab 2 enfortumab vedotin 2 Gemcitabine 2 Carboplatin 2 zimberelimab 1 sirtratumab vedotin 1 sacituzumab govitecan 1 olaparib 1 avelumab 1 Oxaliplatin 1 Nivolumab 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Urothelial Cancer × zimberelimab × Clear all

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡